{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-009462","form_type":"8-K","ticker":"SIGY","cik":"0001642159","company_name":"Sigyn Therapeutics, Inc.","filed_at":"2025-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.280741+00:00","generated_at":"2026-05-25T03:44:54.116231+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Sigyn Therapeutics CFO Gerald DeCiccio Retires; CEO James Joyce Appointed Interim CFO","bullets":["CFO Gerald DeCiccio retired effective February 26, 2025, with no disagreement with the company.","CEO James Joyce will serve as interim CFO following DeCiccio's retirement.","Sigyn entered into a Consulting Agreement with DeCiccio for continued financial support services.","CEO released a letter on March 5, 2025, outlining Sigyn Therapy's potential against emerging viral threats.","Sigyn Therapy targets viruses, bacterial toxins, inflammatory cytokines, and has a clinical strategy for ESRD patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-009462","json":"https://secwatch.observer/filing/0001493152-25-009462.json","markdown":"https://secwatch.observer/filing/0001493152-25-009462.md","text":"https://secwatch.observer/filing/0001493152-25-009462.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1642159/000149315225009462/0001493152-25-009462-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1642159/000149315225009462/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-25T03:44:54.116231+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"39e757b58f","claim":"James Joyce was appointed as interim Chief Financial Officer at Sigyn Therapeutics, Inc..","evidence_excerpt":"Mr. James Joyce, our Chief Executive Officer, will serve as our interim Chief Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1642159/000149315225009462/0001493152-25-009462-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"a45e266906","claim":"Gerald DeCiccio retired as Chief Financial Officer at Sigyn Therapeutics, Inc..","evidence_excerpt":"On February 26, 2025, our Chief Financial Officer, Mr. Gerald DeCiccio provided us a notice of retirement, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1642159/000149315225009462/0001493152-25-009462-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}